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Introduction: Systemic sclerosis is an autoimmune disease which shows extreme hetero-
geneity in its clinical presentation and that follows a variable and unpredictable course.
Although some discrepancies in the incidence and prevalence rates between geographical
regions may reﬂect methodological differences in the deﬁnition and veriﬁcation of cases,
they may also reﬂect true local differences.
Objectives: To determine the prevalence and incidence of systemic sclerosis in the city of
Campo Grande, state capital of Mato Grosso do Sul (MS), Brazil, during the period from
January to December 2014.
Methods: All health care services of the city of Campo Grande – MS with attending in the spe-
cialty of Rheumatology were invited to participate in the study through a standardized formPlease cite this article in press as: Horimoto AMC, et al. Incidence and prevalence of systemic sclerosis in Campo Grande, State of Mato Grosso
do Sul, Brazil. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.09.005
razil of  clinical and socio-demographic assessment. Physicians of any specialty could report a
suspected case of systemic sclerosis, but necessarily the deﬁnitive diagnosis should be estab-
lished by a rheumatologist, in order to warrant the standardization of diagnostic criteria
and  exclusion of other diseases resembling systemic sclerosis. At the end of the study,
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15 rheumatologists reported that they attended patients with systemic sclerosis and sent
the  completed forms containing epidemiological data of patients.
Results: The incidence rate of systemic sclerosis in Campo Grande for the year 2014 was 11.9
per  million inhabitants and the prevalence rate was 105.6 per million inhabitants. Systemic
sclerosis patients were mostly women, white, with a mean age of 50.58 years, showing the
limited form of the disease with a mean duration of the disease of 8.19 years. Regarding
laboratory tests, 94.4% were positive for antinuclear antibody, 41.6% for anti-centromere
antibody and 19.1% for anti-Scl70; anti-RNA Polymerase III was performed in 37 patients,
with 16.2% positive.
Conclusions: The city of Campo Grande, the state capital of MS, presented a lower inci-
dence/prevalence of systemic sclerosis in comparison with those numbers found in US
studies and close to European studies’ data.
Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduc¸ão: A esclerose sistêmica (ES) é uma enfermidade autoimune, extremamente het-
erogênea na sua apresentac¸ão clínica e segue um curso variável e imprevisível. Embora
algumas discrepâncias nas taxas de incidência e prevalência entre regiões possam reﬂe-
tir  as diferenc¸as metodológicas na deﬁnic¸ão e veriﬁcac¸ão dos casos, elas também podem
reﬂetir as verdadeiras diferenc¸as locais.
Objetivos: Conhecer a prevalência e incidência da ES na cidade de Campo Grande, capital
do  Estado de Mato Grosso do Sul (MS), Brasil, de janeiro a dezembro de 2014.
Métodos: Todos os servic¸os de saúde de Campo Grande (MS) que tinham atendimentos na
especialidade de reumatologia foram convidados a participar do estudo por meio de ﬁcha
padronizada de avaliac¸ão clínica e sociodemográﬁca. Médicos de qualquer especialidade
poderiam reportar um caso suspeito de ES, mas obrigatoriamente o diagnóstico deﬁni-
tivo deveria ser feito por um reumatologista, para garantir a padronizac¸ão dos critérios
diagnósticos e excluir outras doenc¸as que se assemelham à ES. No ﬁm do estudo 15 reuma-
tologistas relataram ter atendido pacientes com diagnóstico de ES e enviaram os formulários
preenchidos com os dados epidemiológicos dos pacientes.
Resultados: A taxa de incidência de ES em Campo Grande em 2014 foi de 11,9 por mil-
hão/habitantes e a de prevalência foi de 105,6 por milhão/habitantes. Os pacientes com
ES  eram principalmente mulheres, da cor branca, média de 50,58 anos, forma limitada da
doenc¸a  e tempo de evoluc¸ão médio da doenc¸a de 8,19 anos. Em relac¸ão aos exames lab-
oratoriais, observou-se a positividade de 94,4% para o ANA, 41,6% para ACA e 19,1% para
anti-Scl70, o anticorpo anti-POL3 foi feito em apenas 37 pacientes, com positividade de
16,2%.
Conclusões: A capital do Estado de Mato Grosso do Sul, Campo Grande, apresentou dados
de  incidência e prevalência de ES inferiores aos encontrados em estudos americanos e
próximos aos dados observados em estudos europeus.
Publicado por Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma  licenc¸a CCIntroduction
Systemic sclerosis (SSc) is an autoimmune disease of the
connective tissue, extremely heterogeneous in its clinical pre-
sentation, with the involvement of multiple systems and
1Please cite this article in press as: Horimoto AMC, et al. Incidence and pre
do Sul, Brazil. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.201
that follows a varied and unpredictable course. Its etiol-
ogy remains unknown; a multifactorial cause was suggested,
possibly triggered by environmental factors in a genetically
predisposed individual.2BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The classiﬁcation of SSc patients takes into account the
extension of skin involvement and the presence of over-
lapping with certain characteristics of other autoimmune
rheumatic diseases.3–5
In the United States, the reported prevalence rate for SSc
was 1–5 per 1000 inhabitants. Two prevalence studies con-valence of systemic sclerosis in Campo Grande, State of Mato Grosso
6.09.005
ducted in England found a similar value, about 1 per 1000
inhabitants.4 Regarding the incidence of SSc, an annual rate
of 0.6–19 new cases per million inhabitants was estimated.5
Steen et al. found an incidence rate of SSc in 3.8–13.9 new
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ases per million inhabitants per year.3 A study in a south-
rn state in Australia reported an annual incidence of 22.8
ew cases of SSc per million inhabitants and a prevalence of
33 cases per million inhabitants in 1999, with values sim-
lar to those in American studies conducted in the same
eriod.6
More  recently, a systematic review study reported similar
revalences of SSc observed in the UK and Japan, with 31 and
8 cases per million inhabitants, respectively.7 It is noteworthy
hat, in addition to regional genetic variations, environmental
xposures can also have an effect on the prevalence and inci-
ence rates. For example, silica exposure appears to increase
he risk of developing SSc; however, this triggering action is
nly important to a small proportion of male patients.7
Interestingly, there has been an increase in SSc incidence
ates in different geographical regions,6,8 possibly due to an
arlier diagnosis and also to the use of new classiﬁcation crite-
ia. For example, in the United States, the rate for new cases
ncreased from 0.6 cases per million in 1947 in Tennessee
o 19.0 cases per million in 1991 in the Detroit area.9 Like-
ise, the prevalence and incidence of SSc appear to be larger
n populations of European ancestry, and lower in groups
f Asian descent.7 In Taiwan, the incidence and prevalence
ates were 10.9 and 56.3 cases per million cases/inhabitants,
espectively.10
In epidemiology studies of SSc, different results are
bserved in different regions of the world, and this also
ccurs in one same country or city.6–8,10 SSc prevalence data
n a multi-ethnic French district suggested that the disease
ppears to be more  frequent and severe in a population of
on-European origin, which speaks in favor of the idea that
he race could inﬂuence the susceptibility to the development
f SSc, and also the clinical proﬁle.11 In this same line, the
uropean group of SSc research pointed out that geographi-
al variations in patients with SSc may also have an inﬂuence
ith regard to antibody associations and in the rate of occur-
ence among women and men, but no associations between
aces were found.12
There are no published data on the prevalence and inci-
ence of SSc in the Brazilian population, since this is a
are condition. Thus, due to the scarcity of national studies
nd the high degree of miscegenation found in the Brazilian
opulation13 we aimed to study the prevalence and incidence
f systemic sclerosis in the city of Campo Grande, the state
apital of Mato Grosso do Sul, Brazil, during the period from
anuary to December 2014.
bjectives
o determine the prevalence and incidence of systemic scle-
osis in the city of Campo Grande, Mato Grosso do Sul, Brazil,
uring the period from January to December 2014.
ethodsPlease cite this article in press as: Horimoto AMC, et al. Incidence and pre
do Sul, Brazil. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.201
ll health care services in Campo Grande – MS with Rheuma-
ology specialty participated in this prospective observational
tudy. 6;x  x x(x x):xxx–xxx 3
The Rheumatology units in the city are distributed among
the Medical School Teaching Hospital of the Universidade Fed-
eral de Mato Grosso do Sul, the Regional Hospital of Mato
Grosso do Sul, Santa Casa de Campo Grande, the outpatient
clinic of the Medical Specialties Center of the Municipality of
Campo Grande, outpatient clinics of the Medical Specialties
Center of Anhanguera-Uniderp Medicine School, outpatient
clinics of the Caixa de Assistência dos Servidores de Mato
Grosso do Sul, and several private Rheumatology clinics.
Prior to starting this study, all rheumatologists were
informed by e-mail and phone call about the procedures
for data collection and objectives of this research. Period-
ically, we  asked (by e-mail or phone call) to all involved
doctors to complete a standardized form for collecting demo-
graphic and laboratory data of all patients diagnosed with
systemic sclerosis and evaluated during the study period,
regardless of whether they were new or old cases. Any doc-
tor could report a suspected case of SSc (general practitioner,
dermatologist, vascular surgeon, gastroenterologist, pulmo-
nologist, etc.), but the deﬁnitive diagnosis necessarily should
be established by a rheumatologist, in order to ensure the stan-
dardization of diagnostic criteria and to rule out other diseases
resembling SSc, for example, mixed connective tissue disease
(MCTD).
At the end of the study, 15 rheumatologists reported
patients with SSc, and sent the completed forms with epi-
demiological data of their patients; verbal or written consent
from all patients was requested. The reasons for other MS
rheumatologists did not report cases were: they did not exam-
ine patients with SSc in the period, or the patients seen did not
live in Campo Grande – MS or the patients had already been
reported by another colleague (patient’s duplicity). To avoid
data redundancy in the event that an individual patient had
been assessed by more  than a rheumatologist, these patients
were identiﬁed by the initials of their names and their date of
birth.
Patients diagnosed with SSc and non-residents of Campo
Grande – MS were not considered for incidence and prevalence
estimates.
To be selected, patients with SSc should meet the following
criteria:
- Meet the 2013 classiﬁcation criteria of the ACR/EULAR for
SSc14;
- In the case of absence of skin thickening, patients should
meet the 2001 criteria of LeRoy and Medsger for early SSc.15
State of origin, provenance, age, gender and race/color data,
and time elapsed from ﬁrst symptoms to diagnosis, disease
duration, and clinical form of SSc were collected, and lab-
oratory tests such as antinuclear antibody (ANA) anti-DNA
topoisomerase I antibody (anti Scl70), anticentromere anti-
body (ACA) and anti-RNA polymerase III (anti-RNAP III) also
were conducted.
The methods used in autoantibody survey were, respec-
tively:valence of systemic sclerosis in Campo Grande, State of Mato Grosso
6.09.005
a. Antinuclear antibodies (ANA) survey
Immunoﬂuorescent antibody test for ANA, with HEp2
cells as a substrate (Faar technique), according to the II
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Table 1 – Comparison of incidence and prevalence rates of patients with systemic sclerosis (SSc) in several geographical
regions.
Publication Geographical region Period of study Prevalence per million inhabitants Incidence per million inhabitants
Horimoto et al. Campo Grande – Brazil 2014–2015 105.6 11.9
Rosa et al. Buenos Aires – Argentina 1999–2004 296 21.2
Mayes et al. Detroit – USA 1989–1991 242 19.3
Lo Monaco et al. Ferrara – Italy 1999–2007 254 32
Alamanos et al. Greece 1981–2002 154 11
Thompson et al. Australia 1993–2002 232.2 20.4
Tamaki et al. Tokyo – Japan 1987–1988 38 7.2
Kuo et al. Taiwan 2002–2007 56 10.9
r yearThe results are shown in number of cases per million inhabitants pe
Brazilian Consensus on Antinuclear Factor in Hep-2 cells
(2003) criteria16 for the interpretation of results.
Sera were considered positive with a titer ≥1/160, with dilu-
tion a negative ﬂuorescence.
b. Anticentromere survey – Indirect immunoﬂuorescence
technique with HEp2 cells as a substrate, according to the
II Brazilian Consensus on Antinuclear Factor in Hep-2 cells
(2003) criteria16 for the interpretation of results.
c. Anti-DNA topoisomerase I (anti Scl70) survey – Immunoas-
say technique17; the sample was considered nonreactive
with values <20 units, weakly reactive between 20 and 39
units, moderately reactive between 40 and 80 units and
strongly reactive (higher values) with values >80 units.
d. Anti-RNA polymerase III Antibody survey – ELISA
technique18; the sample was considered negative with
values <20 units, weakly reactive between 20 and 39 units,
moderately reactive between 40 and 80 units, and strongly
reactive (higher values) with >80 units.
Statistical  analysis
IBGE data19 with estimates of the resident population in Brazil
and in Units of the Federation and with a reference date of July
1, 2014, were considered for the calculation of the incidence
and prevalence of SSc.
Data is presented in absolute and relative frequencies,
means and standard deviations, and with a conﬁdence inter-
val of 95% and statistically signiﬁcant values for p < 0.05.
Results
During 2014, a total of 166 patients with scleroderma or sys-
temic sclerosis were treated in various outpatient clinics and
Rheumatology Units in the city of Campo Grande – MS. Eighty-
nine patients who lived in the city had a deﬁnitive diagnosis
of systemic sclerosis and were clinically examined in that city
during the study period.
Of this total, 10 were new cases of SSc diagnosed duringPlease cite this article in press as: Horimoto AMC, et al. Incidence and pre
do Sul, Brazil. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.201
the year 2014 and 79 patients had already been previously
diagnosed. Therefore, the incidence rate of SSc in the city of
Campo Grande – MS  during the year 2014 was 11.9 per mil-
lion inhabitants and the prevalence rate was 105.6 per million.
inhabitants. The data are presented in Table 1, which also
lists comparisons with incidence and prevalence rates in other
countries and regions.
Results  observed  in  systemic  sclerosis
Among the 89 patients with SSc, 86 were women (96.6%) and
3 were men  (3.4%) with a mean age of 50.58 ± 13.85 years
(mean ± standard deviation).
Thirty-one patients (34.8%) with SSc were born in the city of
Campo Grande; 31 patients (34.8%) were born in the country-
side of MT, and 27 patients (30.4%) were born in other states.
Of the 89 patients with SSc, 58 patients (65.2%) reported
being white, 20 patients (22.4%) had a brown color, 8 patients
(9.0%) were black and 3 patients yellow (3.4%).
Regarding clinical forms of SSc, 38 patients (42.7%)
showed the limited form, 24 patients (27.0%) exhibited the
diffuse form, 17 patients (19.1%) show overlapping with
other collagen diseases, 6 patients (6.7%) exhibited the
sine scleroderma form and 4 patients (4.5%) had the early
form. Among the 17 patients with the overlapped form, 8
patients (47.1%) concomitantly had systemic lupus erythe-
matosus, 5 patients (29.4%) had rheumatoid arthritis, and 4
patients (23.5%) had their SSc associated with inﬂammatory
myopathies.
Patients with SSc were already presenting symptoms for
4.74 ± 5.01 years before their diagnosis, and the disease dura-
tion, in general, was about 8.19 ± 7.40 years.
ANA was positive in 84 patients with SSc (94.4%), and the
main patterns found in these patients were: ﬁne speckled
nuclear pattern (30 patients – 36.6%), centromeric pattern (29
patients – 35.4%) and quasi-homogeneous nuclear pattern,
with metaphase plate staining for 5–10 points (12 patients –
14.6%). Among all patients, 37 (41.6%) had positive ACA, 17
(19.1%) were positive for anti-Scl70 and 1 patient (1.1%) was
simultaneously positive for both autoantibodies. On  the other
hand, the anti-RNAP III was performed in only 37 patients,
being positive in 6 of these (16.22%).
The characteristics of the epidemiological proﬁle of
patients with SSc and the results observed in laboratory testsvalence of systemic sclerosis in Campo Grande, State of Mato Grosso
6.09.005
for autoantibodies of the same patients are shown respectively
in Tables 2 and 3.
Please cite this article in press as: Horimoto AMC, et al. Incidence and pre
do Sul, Brazil. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.201
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Table 2 – Distribution of patients evaluated in this study
and results of epidemiological data in patients with
systemic sclerosis (SSc).
Variable Results
Epidemiological data
Age 50.58 ± 13.85
Gender
Male 3 (3.4)
Female 86 (96.6)
Race
White 58 (65.2)
Brown 20 (22.4)
Black 8 (9.0)
Yellow 3 (3.4)
Disease duration
<5 years 33 (37.1)
Between 5 and 10 years 31 (34.8)
>10 years 25 (28.1)
Duration of symptoms before Dx 4.74 ± 5.01
Duration of symptoms after Dx 8.19 ± 7.40
Clinical form
Limited 38 (42.7)
Diffuse 24 (27.0)
Overlap 17 (19.1)
Sine scleroderma 6 (6.7)
Early 4 (4.5)
Dx, diagnosis.
The results are presented as mean ± standard deviation or as abso-
lute frequency (relative frequency).
P-value in Student’s t test or chi-squared test.
Table 3 – Results of autoantibodies in patients with
systemic sclerosis (SSc).
Variable Results
ANA
Positive 84 (94.4)
Negative 5 (5.6)
ANA pattern (n = 84)
Nuclear ﬁne speckled 30 (35.7)
Centromeric 29 (34.5)
Nuclear quasi homogeneous 12 (14.3)
Others 13 (15.5)
Anti-Scl70
Positive 17 (19.1)
Negative 72 (80.9)
ACA
Positive 37 (41.6)
Negative 52 (58.4)
anti-RNAP III (n = 37)
Positive 6 (16.2)
Negative 31 (83.8)
ANA, antinuclear antibody; Scl70, anti-DNA topoisomerase I anti-
body; ACA, anti-centromere antibody; anti-RNAP III, anti-RNA
polymerase III antibody.
The results are presented in absolute frequency (relative frequency).
P-value in Student’s t test or chi-squared test. 6;x  x x(x x):xxx–xxx 5
Discussion
In this study, an unprecedented and representative sample
of the Midwest of Brazil was deﬁned, having been character-
ized by a heterogeneous group of patients with various spectra
of disease and different stages of clinical manifestations and
activities of the disease, but that is very similar to what occurs
in other populations of patients in this country and even from
other locations.3,13,20–23
A systematic review of 32 articles published from 1969 to
2006 indicated that the incidence rate for SSc varied from 0.6
to 122 cases per million inhabitants; on the other hand, the
prevalence rate for the same disease ranged from 7 to 489
cases per million inhabitants,9 which is consistent with the
rates observed in our study. Several geographical variations
were observed, with a higher prevalence of SSc in the United
States (276 cases per million inhabitants) and Australia (233
cases per million inhabitants) versus Japan and Europe, where
one still observed a north–south variable gradient, with lower
prevalence rates in northern European countries.9,12
The rates found for SSc in our study (incidence of 11.9 per
million inhabitants and prevalence of 105.6 per million inha-
bitants) are more  similar to those for European countries. For
example, the prevalence of SSc in a French multi-ethnic dis-
trict was 158.3 cases per million inhabitants in 200111; in the
north of England a prevalence of 88.0 cases per million inha-
bitants in 2000 was found.24 A peculiarity of the city of Campo
Grande – MS  is that its population was mainly composed of
national immigrants and foreigners, who came mainly from
the states of Minas Gerais, Rio Grande do Sul, Parana, and Sao
Paulo, and from countries like Germany, Spain, Italy, Japan,
Paraguay, Portugal, Syria and Lebanon.25
There are no Brazilian studies published on the inci-
dence or prevalence of SSc. In South America, the incidence
and prevalence of SSc observed in Buenos Aires – Argentina
were 21.2 cases and 296 cases per million inhabitants,
respectively.26 In the Caribbean, a lower incidence was
observed, with a total of 17 cases of SSc observed in the
Afro-descendant population of Barbados during an observa-
tion period of 10 years (1996–2006).27 In North America, the
incidence and prevalence of SSc observed in the United States
were higher, respectively 19.3 and 242.0 cases per million
inhabitants.28
Although some discrepancies in the incidence and preva-
lence of SSc between regions may reﬂect methodological
differences in the deﬁnition and veriﬁcation of cases, they
can also reﬂect true local differences. These regional differ-
ences could occur due to the diverse genetic susceptibility to
the development of SSc, or to different degrees of exposure to
environmental factors incriminated in the pathogenesis.6
In Brazil, as in all regions of the world, there were some
differences in the rate of women affected by SSc compared
to men, and female predominance has been observed in
all studies.6,7,10,11,13,20,23,26–38 While there is an agreement
between the results of our study and those in the litera-
ture, a high female/male ratio of 28.6:1 in SSc was observed.valence of systemic sclerosis in Campo Grande, State of Mato Grosso
6.09.005
For example, national data for SSc inform a variable rate
of 7.7–32 women for every affected man13,18,23,37; in South
America (Argentina), the rate is 17:126; in Caribbean countries
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(Barbados and Puerto Rico), the rates are respectively 26:127
and 23:133; in North America (US and Canada), the rates are
respectively 6.1:18 and 7.6:134; in Asia (Taiwan and Japan), the
rates are respectively 3.5:110 and 14:135; in the Middle East
(Iraq), the rate is 8.3:136; and in Europe (Italy, Germany, France
and England), the rates are respectively 9.7:1,37 5:1,21 11.5:1,11
and 5.2:1.24
Regarding other demographic data found, the mean
age of our patients with SSc (50.5 years) was almost
consensus among the various studies in Brazil and
overseas,6,11,13,20–24,28–31,33,34,36,37 with the diagnosis estab-
lished between the fourth and ﬁfth decades of life; only the
African-Caribbean population27 had a younger mean age at
diagnosis (37.3 years). With regard to the race informed by
the patient, there was a prevalence of white color in our
patients with SSc; however, one do not rules out the possi-
bility of a bias of racial classiﬁcation, due to the high degree
of miscegenation found in the Brazilian population.13 In the
South20 and Southeast23 of this country, there was a higher
prevalence of white people with SSc. On the other hand, in the
Northeast38 region, a high prevalence of mulattoes and blacks
was observed, probably because the study was conducted
in a state with a known predominance of Afro-descendants
(Bahia).
In this same vein, the European research group on SSc
(EUSTAR) pointed out that geographical variations in patients
with SSc may also have an impact with regard to antibody
associations and in the rate of occurrence between women
and men,12 but this, as well as another study, found no asso-
ciation between races.12,39 In this study, most patients with
SSc were born in the same state (73.4%), and the remaining
patients were from different locations, but mainly from the
states of São Paulo (13.44%) and Paraná (5.04%).
In this study, the limited clinical presentation of SSc
showed a slight predominance of the diffuse form, in accor-
dance with other descriptions in the country13,20,23,37 and
in most other populations.11,21,22,24,28,33,36 However, there are
descriptions in which the diffuse form is more  common in
populations of Blacks vs. Caucasian populations,11,28,38 includ-
ing, in this case, those of African-Caribbean descent, in which
a predominance of diffuse (63%) over the limited (37%) form
was observed.27
Regarding the laboratory tests performed in patients with
SSc, antinuclear antibody (ANA) was present in 94.4% of
patients – a similar result to most national studies13,20,23,37
and in other regions.11,21,28,36,40–42 The main patterns
observed were: ﬁne speckled nuclear, centromeric, and quasi-
homogeneous nuclear patterns. Bernstein et al. described
ANA positivity in 97% of patients with SSc, mainly repre-
sented by ﬁne speckled and centromeric patterns, besides the
observation of an association with the nucleolar (speckled and
homogenous) pattern in 33% of patients.42 Hesselstrand et al.
reported ANA positivity in 84% of patients with SSc, and the
most observed patterns were: ﬁne speckled (41%), homoge-
neous (25%), nucleolar (24%) and centromeric (18%) patterns.40
Regarding speciﬁc antibodies for SSc observed in this study,
anti-centromere (ACA), anti-DNA topoisomerase I (anti Scl70)Please cite this article in press as: Horimoto AMC, et al. Incidence and pre
do Sul, Brazil. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.201
and anti-RNA polymerase III (anti-RNAP III) positivity was
observed in 41.6%, 19.1% and 16.2% of patients, respectively,
and the percentages were comparable to those in two studies 1 6;x  x x(x x):xxx–xxx
conducted in Southern Brazil,13,20 although Müller et al. had
found surprisingly high levels of anti-RNAP III (41.18%).20 In
this study, 60 of 89 patients (67.4%) were positive for at least
one of those three speciﬁc autoantibodies to SSc (anti-Scl70,
ACA, or anti-RNAP III).
The literature reports that the prevalence of highly speciﬁc
autoantibodies associated with SSc or with overlap syndromes
with SSC features is high in patients with SSc, primarily repre-
sented by ACA and anti Scl70,40–42 here including the Brazilian
population with SSc.13,20 Although the studies report that
the coexistence of these speciﬁc autoantibodies is rare in
patients with SSc (1.6%),40–42 in this study, we  observed two
patients (2.2%) that were concomitantly positive for speciﬁc
autoantibodies: one patient with the diffuse form presented
concomitant positivity for anti Scl70 and ACA, and another
patient also with the diffuse form had concomitant positivity
for anti Scl70 and anti-RNAP III.
Our conclusion is that the city of Campo Grande, the
state capital of Mato Grosso do Sul, presented lower inci-
dence and prevalence of SSc versus those found in American
studies and similar to those observed in European stud-
ies. This incidence, however, may still be underestimated,
especially in patients with the limited form of SSc, because
in these individuals only the Raynaud’s phenomenon is
apparent for many  years, with little systemic involvement;
thus, they may not seek medical attention. We  suggest that
epidemiological surveys in SSc are conducted in other Brazil-
ian cities, in order to reﬂect possible regional differences
and environmental inﬂuences in the development of both
diseases.
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